Skip to content
OpenCapital
Get started

Aardvark Therapeutics, Inc. Common Stock AARD Q4 2024 Annual earnings

Reported February 26, 2025

Diluted EPS-$0.68Miss by $0.27
EPS estimate-$0.41

Next report

Aug 12, 2026 (in a month)
EPS estimate-$0.86

Financials

Q4 2024

Income statement

See full
Operating income-$9.5M—
Net income-$8.8M—
EPS (diluted)-$2.18—

Balance sheet

See full
Cash & equivalents$61.6M—
Total debt$779.0K—
Total equity-$54.6M-57.0%
Total assets$77.5M—

Cash flow

See full
Operating cash flow-$7.7M—
CapEx$6.0K—
Free cash flow-$7.7M—

Versus estimates

Diluted EPS

Q1 2026-$0.99Miss by $0.12Q4 2025-$0.81Beat by $0.02Q3 2025-$0.75Beat by $0.05Q2 2025-$0.66Miss by $0.06Q1 2025-$0.71Miss by $0.04
Q4 2024-$0.68Miss by $0.27

Ask the moment Aardvark Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aardvark Therapeutics, Inc. Common Stock report Q4 2024 earnings?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported Q4 2024 earnings on February 26, 2025.
What were Aardvark Therapeutics, Inc. Common Stock's Q4 2024 revenue and EPS?
Aardvark Therapeutics, Inc. Common Stock reported diluted EPS of $-0.68 for Q4 2024.
Did Aardvark Therapeutics, Inc. Common Stock beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.41 by $0.27.
Where can I find Aardvark Therapeutics, Inc. Common Stock's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-047835) directly on SEC EDGAR. The filing index links above go to sec.gov.